



## Medicare Part D 2025 Formulary Changes - Imperial Giveback (HMO)

Imperial Health Plan of California, Inc. (HMO) (HMO SNP) may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization, quantity limits and/or step therapy restrictions or move a drug to a higher cost-sharing tier, we will notify affected members in writing of the change at least 30 days before the date that the change becomes effective. However, if the U.S. Food and Drug Administration (FDA) determines a drug on our formulary to be unsafe or the drug's manufacturer removes the drug from the market, we will immediately remove the drug from our drug formulary and notify affected members retrospectively in writing. The table below outlines changes made to our formulary throughout 2025.

**VERSION: 14**  
**FORMULARY ID: 25225**

### 2025 FORMULARY UPDATE AS OF August 1, 2025:

| Formulary additions, reductions in preferred or tiered cost-sharing status, or removal of Utilization Management to an existing formulary drug. |                                                    |                       |                          |      |                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-----------------------|--------------------------|------|------------------------------|
| Covered Drug Name                                                                                                                               | Alternate Drug Name                                | Description of Change | Effective Date of Change | Tier | Utilization Management Notes |
| EXKIVITY 40 MG ORAL CAPSULES                                                                                                                    | MOBOCERTINIB SUCCINATE 40 MG ORAL CAPSULES         | DELETION              | 1/1/2025                 | 1    |                              |
| PROMETHAZINE HCL 25 MG/ML INJECTION SOLUTION                                                                                                    | PROMETHAZINE HCL 25 MG/ML INJECTION SOLUTION       | ADDITION              | 1/1/2025                 | 1    |                              |
| SODIUM FLUORIDE SENSITIVE 1.1 %-5 % DENTAL PASTE                                                                                                | SODIUM FLUORIDE/POTASSIUM NIT 1.1 %-5 % ORAL PASTE | ADDITION              | 1/1/2025                 | 1    |                              |
| SODIUM FLUORIDE 0.2 % DENTAL SOLUTION                                                                                                           | FLUORIDE (SODIUM) 0.2 % SOLUTION                   | ADDITION              | 1/1/2025                 | 1    |                              |
| DENTAGEL 1.1 % DENTAL GEL                                                                                                                       | FLUORIDE (SODIUM) 1.1 % GEL                        | ADDITION              | 1/1/2025                 | 1    |                              |
| SF 5000 PLUS 1.1 % DENTAL CREAM                                                                                                                 | FLUORIDE (SODIUM) 1.1 % CREAM                      | ADDITION              | 1/1/2025                 | 1    |                              |
| DENTA 5000 PLUS 1.1 % DENTAL CREAM                                                                                                              | FLUORIDE (SODIUM) 1.1 % CREAM                      | ADDITION              | 1/1/2025                 | 1    |                              |

|                                          |                                            |        |          |   |  |
|------------------------------------------|--------------------------------------------|--------|----------|---|--|
| SEVELAMER CARBONATE 0.8 G ORAL POWD PACK | SEVELAMER CARBONATE 0.8 G ORAL POWDER PACK | UPDATE | 1/1/2025 | 1 |  |
| SEVELAMER CARBONATE 2.4 G ORAL POWD PACK | SEVELAMER CARBONATE 2.4 G ORAL POWDER PACK | UPDATE | 1/1/2025 | 1 |  |
|                                          |                                            |        |          |   |  |

**Formulary additions, reductions in preferred or tiered cost-sharing status, or removal of Utilization Management to an existing formulary drug.**

| Covered Drug Name                | Alternate Drug Name                        | Description of Change | Effective Date of Change | Tier | Utilization Management Notes |
|----------------------------------|--------------------------------------------|-----------------------|--------------------------|------|------------------------------|
| BUDESONIDE 2 MG RECTAL FOAM/APPL | BUDESONIDE 2 MG RECTAL FOAM/APPL           | UPDATE                | 1/1/2025                 |      | Removed Step Therapy         |
| SPRYCEL 100 MG ORAL TABLET       | DASATINIB 100 MG ORAL TABLET               | DELETION              | 2/1/2025                 |      |                              |
| SPRYCEL 140 MG ORAL TABLET       | DASATINIB 140 MG ORAL TABLET               | DELETION              | 2/1/2025                 |      |                              |
| SPRYCEL 20 MG ORAL TABLET        | DASATINIB 20 MG ORAL TABLET                | DELETION              | 2/1/2025                 |      |                              |
| SPRYCEL 50 MG ORAL TABLET        | DASATINIB 50 MG ORAL TABLET                | DELETION              | 2/1/2025                 |      |                              |
| SPRYCEL 70 MG ORAL TABLET        | DASATINIB 70 MG ORAL TABLET                | DELETION              | 2/1/2025                 |      |                              |
| SPRYCEL 80 MG ORAL TABLET        | DASATINIB 80 MG ORAL TABLET                | DELETION              | 2/1/2025                 |      |                              |
| DATROWAY 100 MG IV VIAL          | DATOPOTAMAB DERUXTECAN-DLNK 100 MG IV VIAL | ADDITION              | 2/1/2025                 | 1    | Add PA                       |

|                                                           |                                                                |          |           |   |                  |
|-----------------------------------------------------------|----------------------------------------------------------------|----------|-----------|---|------------------|
| LEVETIRACETAM 250 MG TABLET FOR SUSPENSION                | LEVETIRACETAM 250 MG TABLET FOR SUSPENSION                     | ADDITION | 2/1/2025  | 1 | Add Step Therapy |
| NIKTIMVO 22 MG/.44 ML IV VIAL, 9 MG/0.18 ML IV VIAL       | AXATILIMAB-CSFR 22 MG/.44 ML IV VIAL, 9 MG/0.18 ML IV VIAL     | ADDITION | 2/8/2025  | 1 | Add PA           |
| PHENYTEK 200 MG, 300 MG ORAL CAPSULE                      | PHENYTOIN SODIUM EXTENDED 200 MG, 300 MG ORAL CAPSULE          | ADDITION | 2/8/2025  | 1 |                  |
| ELAHERE 100MG/20ML IV VIAL                                | MIRVETUXIMAB SORAVTANSINE-GYNX 100MG/20ML IV VIAL              | ADDITION | 2/8/2025  | 1 | Add PA           |
| DEXTROSE 5 % AND 0.9 % NACL IV SOLUTION                   | GLUCOSE 5%-0.9% NACL IV SOLUTION                               | ADDITION | 2/8/2025  | 1 |                  |
| GRISEOFULVIN ULTRAMICROSIZED 165 MG ORAL TABLET           | GRISEOFULVIN ULTRAMICROSIZED 165 MG ORAL TABLET                | ADDITION | 2/15/2025 | 1 |                  |
| VELTASSA 1 G ORAL POWDER PACK                             | PATIRROMER CALCIUM SORBITE 1 G ORAL POWDER PACK                | ADDITION | 2/22/2025 | 1 |                  |
| NORETHINDRONE-E. ESTRADIOL-IRON 1.5-30(21) ORAL TABLET    | FEIRZA 1.5-30(21) ORAL TABLET                                  | ADDITION | 2/22/2025 | 1 |                  |
| ULTRA-FINE INSULIN SYRINGE 31GX15/64" DISPOSABLE SYRINGES | SYRGE-NDL, INS 0.3 ML HALF MARK 31GX15/64" DISPOSABLE SYRINGES | ADDITION | 2/22/2025 | 1 | Add Step Therapy |
| ULTRA-FINE PEN NEEDLE 29 G X1/2" DISPOSABLE NEEDLES       | PEN NEEDLE, DIABETIC 29 G X1/2" DISPOSABLE NEEDLES             | ADDITION | 2/22/2025 | 1 | Add Step Therapy |
| ETHYNODIOL D-ETHINYL ESTRADIOL 1 MG-50MCG ORAL TABLET     | VALTYA 1 MG-50MCG ORAL TABLET                                  | ADDITION | 2/22/2025 | 1 |                  |
|                                                           |                                                                |          |           |   |                  |

**Formulary additions, reductions in preferred or tiered cost-sharing status, or removal of Utilization Management to an existing formulary drug.**

| <b>Covered Drug Name</b>                              | <b>Alternate Drug Name</b>                           | <b>Description of Change</b> | <b>Effective Date of Change</b> | <b>Tier</b> | <b>Utilization Management Notes</b> |
|-------------------------------------------------------|------------------------------------------------------|------------------------------|---------------------------------|-------------|-------------------------------------|
| NORETHINDRONE-E.ESTRADIOL-IRON 1MG-20(21) ORAL TABLET | FEIRZA 1MG-20(21) ORAL TABLET                        | ADDITION                     | 3/1/2025                        | 1           |                                     |
| LEVETIRACETAM 250 MG ORAL TABLET FOR SUSPENSION       | LEVETIRACETAM 250 MG ORAL TABLET FOR SUSPENSION      | UPDATE                       | 3/1/2025                        | 1           | Removed Step Therapy                |
| GOMEKLI 1 MG ORAL CAPSULE                             | MIRDAMETINIB 1 MG ORAL CAPSULE                       | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| GOMEKLI 2 MG ORAL CAPSULE                             | MIRDAMETINIB 2 MG ORAL CAPSULE                       | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| GOMEKLI 1 MG ORAL TABLET FOR SUSPENSION               | MIRDAMETINIB 1 MG ORAL TABLET FOR SUSPENSION         | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| RYBELSUS 1.5 MG ORAL TABLET                           | SEMAGLUTIDE 1.5 MG ORAL TABLET                       | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| RYBELSUS 4 MG ORAL TABLET                             | SEMAGLUTIDE 4 MG ORAL TABLET                         | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| RYBELSUS 9 MG ORAL TABLET                             | SEMAGLUTIDE 9 MG ORAL TABLET                         | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| ONAPGO 98 MG/20ML SUBCUTANEOUS CARTRIDGE              | APOMORPHINE HCL 98 MG/20ML SUBCUTANEOUS CARTRIDGE    | ADDITION                     | 3/1/2025                        | 1           | Add PA, Quantity Limit              |
| VIMKUNYA 40 MCG/0.8 IM SYRINGE                        | CHIKUNGUNYA VACCINE, RECOMB/PF 40 MCG/0.8 IM SYRINGE | ADDITION                     | 3/8/2025                        | 1           |                                     |
| MERCAPTOPURINE 2000 MG/100 ML ORAL SUSPENSION         | MERCAPTOPURINE 2000 MG/100 ML ORAL SUSPENSION        | ADDITION                     | 3/15/2025                       | 1           |                                     |

|                                                           |                                                             |          |           |   |                        |
|-----------------------------------------------------------|-------------------------------------------------------------|----------|-----------|---|------------------------|
| ABIRATERONE ACETATE 250 MG ORAL TABLET                    | ABIRTEGA 250 MG ORAL TABLET                                 | ADDITION | 3/15/2025 | 1 | Add PA, Quantity Limit |
| ROMVIMZA 14 MG ORAL CAPSULE                               | VIMSELTINIB 14 MG ORAL CAPSULE                              | ADDITION | 3/15/2025 | 1 | Add PA, Quantity Limit |
| ROMVIMZA 20 MG ORAL CAPSULE                               | VIMSELTINIB 20 MG ORAL CAPSULE                              | ADDITION | 3/15/2025 | 1 | Add PA, Quantity Limit |
| ROMVIMZA 30 MG ORAL CAPSULE                               | VIMSELTINIB 30 MG ORAL CAPSULE                              | ADDITION | 3/15/2025 | 1 | Add PA, Quantity Limit |
| RALDESY 10 MG/ML ORAL SOLUTION                            | TRAZODONE HCL 10 MG/ML ORAL SOLUTION                        | ADDITION | 3/15/2025 | 1 | Add PA, Quantity Limit |
| VIVOTIF ORAL CAPSULE DELAYED RELEASE 2 BILLION UNIT       | THPHOID VACCINE ORAL CAPSULE DELAYED RELEASE 2 BILLION UNIT | ADDITION | 3/15/2025 | 1 |                        |
| DABIGATRAN ETEXILATE MESYLATE 110 MG ORAL CAPSULE         | DABIGATRAN ETEXILATE 110 MG ORAL CAPSULE                    | ADDITION | 3/22/2025 | 1 | Add Quantity Limit     |
| DABIGATRAN ETEXILATE MESYLATE 150 MG ORAL CAPSULE         | DABIGATRAN ETEXILATE 150 MG ORAL CAPSULE                    | ADDITION | 3/22/2025 | 1 | Add Quantity Limit     |
| DABIGATRAN ETEXILATE MESYLATE 75 MG ORAL CAPSULE          | DABIGATRAN ETEXILATE 75 MG ORAL CAPSULE                     | ADDITION | 3/22/2025 | 1 | Add Quantity Limit     |
| XPOVIO (40 MG ONCE WEEKLY) 10 MG ORAL TABLET THERAPY PACK | SELINEXOR 10 MG ORAL TABLET THERAPY PACK                    | ADDITION | 3/22/2025 | 1 | Add PA, Quantity Limit |
| IVERMECTIN 6 MG ORAL TABLET                               | IVERMECTIN 6 MG ORAL TABLET                                 | ADDITION | 3/29/2025 | 1 |                        |
| REVUFORJ 25 MG ORAL TABLET                                | REVUMENIB CITRATE 25 MG ORAL TABLET                         | ADDITION | 3/29/2025 | 1 | Add PA, Quantity Limit |
| SELARSDI 130MG/26ML IV VIAL                               | USTEKINUMAB-AEKN 130MG/26ML IV VIAL                         | ADDITION | 3/29/2025 | 1 | Add PA                 |
| MESNA 400 MG ORAL TABLET                                  | MESNEX 400 MG ORAL TABLET                                   | DELETION | 4/1/2025  |   |                        |
| SELARSDI 45MG/0.5ML SUBCUTANEOUS SYRINGE                  | USTEKINUMAB-AEKN 45MG/0.5ML SUBCUTANEOUS SYRINGE            | ADDITION | 4/1/2025  | 1 | Add PA                 |
| CYLTEZO(CF) 40MG/0.8ML                                    | ADALIMUMAB-ADBIM 40MG/0.8ML SUBCUTANEOUS SYRINGE KIT        | ADDITION | 4/1/2025  | 1 | Add PA                 |

|                                                                        |                                                           |          |          |   |        |
|------------------------------------------------------------------------|-----------------------------------------------------------|----------|----------|---|--------|
| SUBCUTANEOUS SYRINGE KIT                                               |                                                           |          |          |   |        |
| CYLTEZO(CF) PEN CROHN'S-UC-HS 40MG/0.8ML SUBCUTANEOUS PEN INJECTOR KIT | ADALIMUMAB-ADBIM 40MG/0.8ML SUBCUTANEOUS PEN INJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN PSORIASIS-UV 40MG/0.8ML SUBCUTANEOUS PEN INJECTOR KIT  | ADALIMUMAB-ADBIM 40MG/0.8ML SUBCUTANEOUS PEN INJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN 40MG/0.8ML SUBCUTANEOUS PEN INJECTOR KIT               | ADALIMUMAB-ADBIM 40MG/0.8ML SUBCUTANEOUS PEN INJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN 10MG/0.2ML SUBCUTANEOUS SYRINGE KIT                    | ADALIMUMAB-ADBIM 10MG/0.2ML SUBCUTANEOUS SYRINGE KIT      | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN 20MG/0.4ML SUBCUTANEOUS SYRINGE KIT                    | ADALIMUMAB-ADBIM 20MG/0.4ML SUBCUTANEOUS SYRINGE KIT      | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN 40MG/0.4ML SUBCUTANEOUS SYRINGE KIT                    | ADALIMUMAB-ADBIM 40MG/0.4ML SUBCUTANEOUS SYRINGE KIT      | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN PSORIASIS-UV 40MG/0.4ML SUBCUTANEOUS PEN INJECTOR KIT  | ADALIMUMAB-ADBIM 40MG/0.4ML SUBCUTANEOUS PEN INJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN 40MG/0.4ML SUBCUTANEOUS PEN INJECTOR KIT               | ADALIMUMAB-ADBIM 40MG/0.4ML SUBCUTANEOUS PEN INJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| CYLTEZO(CF) PEN CROHN'S-UC-HS 40MG/0.4ML SUBCUTANEOUS PEN INJECTOR KIT | ADALIMUMAB-ADBIM 40MG/0.4ML SUBCUTANEOUS PEN INJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| TYENNE AUTOINJECTOR 162 MG/0.9 SUBCUTANEOUS PEN INJECTOR               | TOCILIZUMAB-AAZG 162 MG/0.9 SUBCUTANEOUS PEN INJECTOR     | ADDITION | 4/1/2025 | 1 | Add PA |
| TYENNE 162 MG/0.9 SUBCUTANEOUS SYRINGE                                 | TOCILIZUMAB-AAZG 162 MG/0.9 SUBCUTANEOUS SYRINGE          | ADDITION | 4/1/2025 | 1 | Add PA |
| TYENNE 80 MG/4 ML IV VIAL                                              | TOCILIZUMAB-AAZG 80 MG/4 ML IV VIAL                       | ADDITION | 4/1/2025 | 1 | Add PA |
| TYENNE 200 MG/10 ML IV VIAL                                            | TOCILIZUMAB-AAZG 200 MG/10 ML IV VIAL                     | ADDITION | 4/1/2025 | 1 | Add PA |

|                                                                       |                                                          |          |          |   |        |
|-----------------------------------------------------------------------|----------------------------------------------------------|----------|----------|---|--------|
| TYENNE 400 MG/20 ML IV VIAL                                           | TOCILIZUMAB-AAZG 400 MG/20 ML IV VIAL                    | ADDITION | 4/1/2025 | 1 | Add PA |
| YUFLYMA(CF) AUTOINJECTOR 80MG/0.8ML SUBCUTANEOUS AUTOINJECTOR KIT     | ADALIMUMAB-AATY 80MG/0.8ML SUBCUTANEOUS AUTOINJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| YUFLYMA(CF) AI CROHN'S-UC-HS 80MG/0.8ML SUBCUTANEOUS AUTOINJECTOR KIT | ADALIMUMAB-AATY 80MG/0.8ML SUBCUTANEOUS AUTOINJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| YUFLYMA(CF) 20MG/0.2ML SUBCUTANEOUS SYRINGE KIT                       | ADALIMUMAB-ADB 20MG/0.2ML SUBCUTANEOUS SYRINGE KIT       | ADDITION | 4/1/2025 | 1 | Add PA |
| YUFLYMA(CF) 40MG/0.4 ML SUBCUTANEOUS SYRINGE KIT                      | ADALIMUMAB-ADB 40MG/0.4ML SUBCUTANEOUS SYRINGE KIT       | ADDITION | 4/1/2025 | 1 | Add PA |
| YUFLYMA(CF) AUTOINJECTOR 40MG/0.4ML SUBCUTANEOUS AUTOINJECTOR KIT     | ADALIMUMAB-AATY 40MG/0.4ML SUBCUTANEOUS AUTOINJECTOR KIT | ADDITION | 4/1/2025 | 1 | Add PA |
| YESINTEK 45MG/0.5ML SUBCUTANEOUS SYRINGE                              | USTEKINUMAB-KFCE 45MG/0.5ML SUBCUTANEOUS SYRINGE         | ADDITION | 4/1/2025 | 1 | Add PA |
| YESINTEK 45MG/0.5ML SUBCUTANEOUS VIAL                                 | USTEKINUMAB-KFCE 45MG/0.5ML SUBCUTANEOUS VIAL            | ADDITION | 4/1/2025 | 1 | Add PA |
| YESINTEK 90MG/ML SUBCUTANEOUS SYRINGE                                 | USTEKINUMAB-KFCE 90MG/ML SUBCUTANEOUS SYRINGE            | ADDITION | 4/1/2025 | 1 | Add PA |
| YESINTEK 130MG/26ML IV VIAL                                           | USTEKINUMAB-KFCE 130MG/26ML IV VIAL                      | ADDITION | 4/1/2025 | 1 | Add PA |
| TRUSELTIQ 100 MG/DAY ORAL CAPSULE                                     | INFIGRATINIB PHOSPHATE 100 MG/DAY ORAL CAPSULE           | DELETION | 4/1/2025 |   |        |
| TRUSELTIQ 125 MG/DAY ORAL CAPSULE                                     | INFIGRATINIB PHOSPHATE 125 MG/DAY ORAL CAPSULE           | DELETION | 4/1/2025 |   |        |
| TRUSELTIQ 50 MG/DAY ORAL CAPSULE                                      | INFIGRATINIB PHOSPHATE 50 MG/DAY ORAL CAPSULE            | DELETION | 4/1/2025 |   |        |
| TRUSELTIQ 75 MG/DAY ORAL CAPSULE                                      | INFIGRATINIB PHOSPHATE 75 MG/DAY ORAL CAPSULE            | DELETION | 4/1/2025 |   |        |

**Formulary additions, reductions in preferred or tiered cost-sharing status, or removal of Utilization Management to an existing formulary drug.**

| <b>Covered Drug Name</b>                                   | <b>Alternate Drug Name</b>                                       | <b>Description of Change</b> | <b>Effective Date of Change</b> | <b>Tier</b> | <b>Utilization Management Notes</b> |
|------------------------------------------------------------|------------------------------------------------------------------|------------------------------|---------------------------------|-------------|-------------------------------------|
| SELARSDI 130 MG/26 ML IV SOLUTION                          | USTEKINUMAB-AEKN (IV) 130 MG/26 ML                               | ADDITION                     | 4/5/2025                        | 1           | Add PA                              |
| TREMFYA CROHNS INDUCTION 200 MG/2 ML SUBCUTANEOUS INJECTOR | GUSELKUMAB (GASTROINTESTINAL) 200 MG/ 2 ML SUBCUTANEOUS INJECTOR | ADDITION                     | 4/5/2025                        | 1           | Add PA                              |
| ACYCLOVIR 800 MG/20ML ORAL SUSPENSION                      | ACYCLOVIR 800 MG/20ML ORAL SUSPENSION                            | ADDITION                     | 4/5/2025                        | 1           |                                     |
| TREMFYA PEN 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR           | GUSELKUMAB 100 MG/ML SUBCUTANEOUS AUTO-INJECTOR                  | ADDITION                     | 4/12/2025                       | 1           | Add PA                              |
| REXULTI 0.25MG ORAL TABLET                                 | BREXPIRAZOLE 0.25MG ORAL TABLET                                  | UPDATE                       | 4/12/2025                       |             | Remove Step Therapy                 |
| REXULTI 0.5MG ORAL TABLET                                  | BREXPIRAZOLE 0.5MG ORAL TABLET                                   | UPDATE                       | 4/12/2025                       |             | Remove Step Therapy                 |
| REXULTI 1MG ORAL TABLET                                    | BREXPIRAZOLE 1MG ORAL TABLET                                     | UPDATE                       | 4/12/2025                       |             | Remove Step Therapy                 |
| REXULTI 2MG ORAL TABLET                                    | BREXPIRAZOLE 2MG ORAL TABLET                                     | UPDATE                       | 4/12/2025                       |             | Remove Step Therapy                 |
| REXULTI 3MG ORAL TABLET                                    | BREXPIRAZOLE 3MG ORAL TABLET                                     | UPDATE                       | 4/12/2025                       |             | Remove Step Therapy                 |
| REXULTI 4MG ORAL TABLET                                    | BREXPIRAZOLE 4MG ORAL TABLET                                     | UPDATE                       | 4/12/2025                       |             | Remove Step Therapy                 |
| SELARSDI 45MG/0.5ML SUBCUTANEOUS SYRINGE                   | USTEKINUMAB-AEKN 45MG/0.5ML SUBCUTANEOUS SYRINGE                 | ADDITION                     | 4/16/2025                       | 1           | Remove PA                           |



|                                               |                                                              |          |           |   |                           |
|-----------------------------------------------|--------------------------------------------------------------|----------|-----------|---|---------------------------|
| YESINTEK 45MG/0.5ML SUBCUTANEOUS SYRINGE      | USTEKINUMAB-KFCE 45MG/0.5ML SUBCUTANEOUS SYRINGE             | ADDITION | 4/16/2025 | 1 | Remove PA                 |
| YESINTEK 45MG/0.5ML SUBCUTANEOUS VIAL         | USTEKINUMAB-KFCE 45MG/0.5ML SUBCUTANEOUS VIAL                | ADDITION | 4/16/2025 | 1 | Remove PA                 |
| LUTRATE DEPOT 22.5 MG INTRAMUSCULAR INJECTION | LEUPROLIDE ACETATE (3 MONTH) 22.5 MG INTRAMUSCULAR INJECTION | ADDITION | 4/16/2025 | 1 | Add PA                    |
| VIVIMUSTA 25 MG/ML INTRAVENOUS VIAL           | BENDAMUSTINE HCL 25 MG/ML INTRAVENOUS VIAL                   | ADDITION | 4/19/2025 | 1 | Add PA                    |
| VYLOY 300 MG INTRAVENOUS VIAL                 | ZOLBETUXIMAB-CLZB 300 MG INTRAVENOUS VIAL                    | ADDITION | 4/19/2025 | 1 | Add PA                    |
| DICLOFENAC EPOLAMINE 1.3% TRANSDERMAL PATCH   | DICLOFENAC EPOLAMINE 1.3% TRANSDERMAL PATCH                  | ADDITION | 4/19/2025 | 1 | Add PA and Quantity Limit |
| SUNLENCA 300 MG ORAL TABLET                   | LENACAPAVIR SODIUM 300 MG ORAL TABLET                        | ADDITION | 4/26/2025 | 1 |                           |
| PAXLOVID 150-100 MG ORAL TABLET DOSE PACK     | NIRMATRELVIR/RITONAVIR 150-100 MG ORAL TABLET DOSE PACK      | ADDITION | 4/26/2025 | 1 | Add Quantity Limit        |
| CORTROPHIN 80 UNIT/ML INJECTION VIAL          | CORTICOTROPIN 80 UNIT/ML INJECTION VIAL                      | ADDITION | 5/1/2025  | 1 | Add PA and Quantity Limit |
| BAQSIMI 3 MG NASAL SPRAY                      | GLUCAGON 3 MG NASAL SPRAY                                    | UPDATE   | 5/1/2025  | 1 | Remove Step Therapy       |
| XCOPRI 100 MG ORAL TABLET                     | CENOBAMATE 100 MG ORAL TABLET                                | UPDATE   | 5/1/2025  | 1 | Remove Step Therapy       |
| XCOPRI 12.5-25 MG ORAL TABLET DOSE PACK       | CENOBAMATE 12.5-25 MG ORAL TABLET DOSE PACK                  | UPDATE   | 5/1/2025  | 1 | Remove Step Therapy       |
| XCOPRI 150 MG ORAL TABLET                     | CENOBAMATE 150 MG ORAL TABLET                                | UPDATE   | 5/1/2025  | 1 | Remove Step Therapy       |
| XCOPRI 150-200 MG ORAL TABLET DOSE PACK       | CENOBAMATE 150-200 MG ORAL TABLET DOSE PACK                  | UPDATE   | 5/1/2025  | 1 | Remove Step Therapy       |

|                                             |                                                   |          |          |   |                           |
|---------------------------------------------|---------------------------------------------------|----------|----------|---|---------------------------|
| XCOPRI 200 MG ORAL TABLET                   | CENOBAMATE 200 MG ORAL TABLET                     | UPDATE   | 5/1/2025 | 1 | Remove Step Therapy       |
| XCOPRI 25 MG ORAL TABLET                    | CENOBAMATE 25 MG ORAL TABLET                      | UPDATE   | 5/1/2025 | 1 | Remove Step Therapy       |
| XCOPRI 250 MG/DAY ORAL TABLET               | CENOBAMATE 250 MG/DAY ORAL TABLET                 | UPDATE   | 5/1/2025 | 1 | Remove Step Therapy       |
| XCOPRI 350 MG/DAY ORAL TABLET               | CENOBAMATE 350 MG/DAY ORAL TABLET                 | UPDATE   | 5/1/2025 | 1 | Remove Step Therapy       |
| XCOPRI 50 MG ORAL TABLET                    | CENOBAMATE 50 MG ORAL TABLET                      | UPDATE   | 5/1/2025 | 1 | Remove Step Therapy       |
| XCOPRI 50 MG-100 MG ORAL TABLET DOSE PACK   | CENOBAMATE 50 MG-100 MG ORAL TABLET DOSE PACK     | UPDATE   | 5/1/2025 | 1 | Remove Step Therapy       |
| MIEBO 100 % OPHTHALMIC DROPS                | PERFLUOROHEXYLOCTANE/PF 100 % OPHTHALMIC DROPS    | ADDITION | 5/1/2025 | 1 | Remove PA                 |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS 140 MG/ML | ERENUMAB-AOOE AUTOINJECTOR SUBCUTANEOUS 140 MG/ML | ADDITION | 5/1/2025 | 1 | Add PA and Quantity Limit |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS 70 MG/ML  | ERENUMAB-AOOE AUTOINJECTOR SUBCUTANEOUS 70 MG/ML  | ADDITION | 5/1/2025 | 1 | Add PA and Quantity Limit |

**Formulary additions, reductions in preferred or tiered cost-sharing status, or removal of Utilization Management to an existing formulary drug.**

| Covered Drug Name                      | Alternate Drug Name                    | Description of Change | Effective Date of Change | Tier | Utilization Management Notes |
|----------------------------------------|----------------------------------------|-----------------------|--------------------------|------|------------------------------|
| BISOPROLOL FUMARATE 2.5 MG ORAL TABLET | BISOPROLOL FUMARATE 2.5 mg ORAL TABLET | ADDITION              | 5/3/2025                 | 1    |                              |
| EULEXIN 125 MG ORAL CAPSULE            | FLUTAMIDE 125 MG ORAL CAPSULE          | ADDITION              | 5/3/2025                 | 1    |                              |
| ABIRTEGA 250 MG ORAL TABLET            | ABIRATERONE ACETATE 250MG ORAL TABLET  | UPDATE                | 5/3/2025                 |      | Remove PA and Quantity       |

|                                                                     |                                                                    |          |           |   |                                     |
|---------------------------------------------------------------------|--------------------------------------------------------------------|----------|-----------|---|-------------------------------------|
|                                                                     |                                                                    |          |           |   | Limit                               |
| RALDESY 10 MG/ML ORAL SOLUTION                                      | TRAZODONE HCL 10 MG/ML ORAL SOLUTION                               | UPDATE   | 5/3/2025  |   | Remove PA and Quantity Limit        |
| OPIPZA 10 MG ORAL FILM                                              | ARIPIPRAZOLE 10 MG ORAL FILM                                       | ADDITION | 5/3/2025  | 1 | Add Step Therapy                    |
| OPIPZA 2 MG ORAL FILM                                               | ARIPIPRAZOLE 2 MG ORAL FILM                                        | ADDITION | 5/3/2025  | 1 | Add Step Therapy                    |
| OPIPZA 5 MG ORAL FILM                                               | ARIPIPRAZOLE 5 MG ORAL FILM                                        | ADDITION | 5/3/2025  | 1 | Add Step Therapy                    |
| ESLICARBAZEPINE ACETATE 200 MG ORAL TABLET                          | ESLICARBAZEPINE ACETATE 200 MG ORAL TABLET                         | ADDITION | 5/17/2025 | 1 | Add Step Therapy and Quantity Limit |
| ESLICARBAZEPINE ACETATE 400 MG ORAL TABLET                          | ESLICARBAZEPINE ACETATE 400 MG ORAL TABLET                         | ADDITION | 5/17/2025 | 1 | Add Step Therapy and Quantity Limit |
| ESLICARBAZEPINE ACETATE 600 MG ORAL TABLET                          | ESLICARBAZEPINE ACETATE 600 MG ORAL TABLET                         | ADDITION | 5/17/2025 | 1 | Add Step Therapy and Quantity Limit |
| ESLICARBAZEPINE ACETATE 800 MG ORAL TABLET                          | ESLICARBAZEPINE ACETATE 800 MG ORAL TABLET                         | ADDITION | 5/17/2025 | 1 | Add Step Therapy and Quantity Limit |
| AVMAPKI 0.8 MG ORAL CAPSULE                                         | AVUTOMETINIB POTASSIUM 0.8 MG ORAL CAPSULE                         | ADDITION | 5/24/2025 | 1 | Add PA and Quantity Limit           |
| FAKZYNJA 200 MG ORAL TABLET                                         | DEFACTINIB HYDROCHLORIDE 200 MG ORAL TABLET                        | ADDITION | 5/24/2025 | 1 | Add PA and Quantity Limit           |
| LUTRATE DEPOT 22.5 MG INTRAMUSCULAR VIAL                            | LEUPROLIDE ACETATE 22.5 MG INTRAMUSCULAR VIAL                      | ADDITION | 5/24/2025 | 1 | Add PA                              |
| AVMAPKI FAKZYNJA CO-PACK 0.8 MG AND 200 MG ORAL TABLET THERAPY PACK | AVUTOMETINIB-DEFACTINIB 0.8 MG AND 200 MG ORAL TABLET THERAPY PACK | ADDITION | 5/24/2025 | 1 | Add PA and Quantity Limit           |
| EDURANT PED 2.5 MG TABLET FOR ORAL SOLUTION                         | RILPIVIRINE HCL 2.5 MG TABLET FOR ORAL SOLUTION                    | ADDITION | 5/24/2025 | 1 |                                     |
| EMRELIS 100 MG INTRAVENOUS SOLUTION                                 | TELISOTUZUMAB VEDOTIN-TLLV 100 MG INTRAVENOUS SOLUTION             | ADDITION | 5/31/2025 | 1 | Add PA                              |

|                                                        |                                                        |          |           |   |                                     |
|--------------------------------------------------------|--------------------------------------------------------|----------|-----------|---|-------------------------------------|
| EMRELIS 20 MG INTRAVENOUS SOLUTION                     | TELISOTUZUMAB VEDOTIN-TLLV 20 MG INTRAVENOUS SOLUTION  | ADDITION | 5/31/2025 | 1 | Add PA                              |
| PURIXAN 20 MG/ML ORAL SUSPENSION                       | MERCAPTOPURINE 20 MG/ML ORAL SUSPENSION                | DELETION | 6/1/2025  |   |                                     |
| ELEPSIA XR 1000 MG ER 24H ORAL TABLET                  | LEVETIRACETAM 1000 MG ER 24H ORAL TABLET               | ADDITION | 6/7/2025  | 1 | Add Step Therapy and Quantity Limit |
| ELEPSIA XR 1500 MG ER 24H ORAL TABLET                  | LEVETIRACETAM 1500 MG ER 24H ORAL TABLET               | ADDITION | 6/7/2025  | 1 | Add Step Therapy and Quantity Limit |
| EMTRICITABINE-RILPIVIRNE-TENOF 200-25-300 ORAL TABLET  | EMTRICITA/RILPIVIRINE/TENOF DF 200-25-300 ORAL TABLET  | ADDITION | 6/7/2025  | 1 |                                     |
| HYDROCODONE-ACETAMINOPHEN 10-300 MG/15ML ORAL SOLUTION | HYDROCODONE-ACETAMINOPHEN 10-300 MG/15ML ORAL SOLUTION | ADDITION | 6/14/2025 | 1 | Add Quantity Limit                  |
| PERAMPANEL 10 MG ORAL TABLET                           | PERAMPANEL 10 MG ORAL TABLET                           | ADDITION | 6/14/2025 | 1 | Add Step Therapy and Quantity Limit |
| PERAMPANEL 12 MG ORAL TABLET                           | PERAMPANEL 12 MG ORAL TABLET                           | ADDITION | 6/14/2025 | 1 | Add Step Therapy and Quantity Limit |
| PERAMPANEL 2 MG ORAL TABLET                            | PERAMPANEL 2 MG ORAL TABLET                            | ADDITION | 6/14/2025 | 1 | Add Step Therapy and Quantity Limit |
| PERAMPANEL 4 MG ORAL TABLET                            | PERAMPANEL 4 MG ORAL TABLET                            | ADDITION | 6/14/2025 | 1 | Add Step Therapy and Quantity Limit |
| PERAMPANEL 6 MG ORAL TABLET                            | PERAMPANEL 6 MG ORAL TABLET                            | ADDITION | 6/14/2025 | 1 | Add Step Therapy and Quantity Limit |
| PERAMPANEL 8 MG ORAL TABLET                            | PERAMPANEL 8 MG ORAL TABLET                            | ADDITION | 6/14/2025 | 1 | Add Step Therapy and Quantity Limit |
| MELEYA 0.35 MG ORAL TABLET                             | NORETHINDRONE (CONTRACEPTIVE) 0.35 MG ORAL TABLET      | ADDITION | 6/14/2025 | 1 |                                     |
| CRESEMBA 186 MG ORAL CAPSULE                           | ISAVUCONAZONIUM SULFATE 186 MG ORAL CAPSULE            | ADDITION | 6/14/2025 | 1 | Add PA                              |

|                                              |                                                 |          |           |   |                           |
|----------------------------------------------|-------------------------------------------------|----------|-----------|---|---------------------------|
| CRESEMBA 372 MG INTRAVENOUS VIAL             | ISAVUCONAZONIUM SULFATE 372 MG INTRAVENOUS VIAL | ADDITION | 6/14/2025 | 1 |                           |
| JYNARQUE 15 MG ORAL TABLET                   | TOLVAPTAN 15 MG ORAL TABLET                     | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| JYNARQUE 30 MG ORAL TABLET                   | TOLVAPTAN 30 MG ORAL TABLET                     | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| JYNARQUE 60 MG-30 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 60 MG-30 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| JYNARQUE 45 MG-15 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 45 MG-15 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| JYNARQUE 90 MG-30 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 90 MG-30 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| JYNARQUE 30 MG-15 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 30 MG-15 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| JYNARQUE 15 MG-15 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 15 MG-15 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| CAMZYOS 10 MG ORAL CAPSULE                   | MAVACAMTEN 10 MG ORAL CAPSULE                   | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| CAMZYOS 15 MG ORAL CAPSULE                   | MAVACAMTEN 15 MG ORAL CAPSULE                   | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| CAMZYOS 2.5 MG ORAL CAPSULE                  | MAVACAMTEN 2.5 MG ORAL CAPSULE                  | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| CAMZYOS 5 MG ORAL CAPSULE                    | MAVACAMTEN 5 MG ORAL CAPSULE                    | ADDITION | 6/14/2025 | 1 | Add PA and Quantity Limit |
| CRESEMBA 74.5 MG ORAL CAPSULE                | ISAVUCONAZONIUM SULFATE 74.5 MG ORAL CAPSULE    | ADDITION | 6/14/2025 | 1 | Add PA                    |
| TOLVAPTAN 15 MG-15 MG ORAL TABLET SEQUENTIAL | TOLVAPTAN 15 MG-15 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 |                           |
| TOLVAPTAN 30 MG-15 MG ORAL TABLET SEQUENTIAL | TOLVAPTAN 30 MG-15 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 |                           |
| TOLVAPTAN 45 MG-15 MG ORAL TABLET SEQUENTIAL | TOLVAPTAN 45 MG-15 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 |                           |
| TOLVAPTAN 60 MG-30 MG ORAL TABLET            | TOLVAPTAN 60 MG-30 MG ORAL TABLET SEQUENTIAL    | ADDITION | 6/14/2025 | 1 |                           |

|                                              |                                                      |          |           |   |                  |
|----------------------------------------------|------------------------------------------------------|----------|-----------|---|------------------|
| SEQUENTIAL                                   |                                                      |          |           |   |                  |
| TOLVAPTAN 90 MG-30 MG ORAL TABLET SEQUENTIAL | TOLVAPTAN 90 MG-30 MG ORAL TABLET SEQUENTIAL         | ADDITION | 6/14/2025 | 1 |                  |
| ADVANCED EYE RELIEF 0.20% OPHTHALMIC DROPS   | OLOPATADINE HCL 0.20% OPHTHALMIC DROPS               | ADDITION | 6/28/2025 |   | Add Step Therapy |
| KALETRA 400 MG-100 MG/5 ML ORAL SOLUTION     | LOPINAVIR/RITONAVIR 400 MG-100 MG/5 ML ORAL SOLUTION | ADDITION | 6/28/2025 | 1 |                  |
| JYNARQUE 15 MG-15 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 15 MG-15 MG ORAL TABLET SEQUENTIAL         | DELETION | 8/1/2025  |   |                  |
| JYNARQUE 30 MG-15 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 30 MG-15 MG ORAL TABLET SEQUENTIAL         | DELETION | 8/1/2025  |   |                  |
| JYNARQUE 45 MG-15 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 45 MG-15 MG ORAL TABLET SEQUENTIAL         | DELETION | 8/1/2025  |   |                  |
| JYNARQUE 60 MG-30 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 60 MG-30 MG ORAL TABLET SEQUENTIAL         | DELETION | 8/1/2025  |   |                  |
| JYNARQUE 90 MG-30 MG ORAL TABLET SEQUENTIAL  | TOLVAPTAN 90 MG-30 MG ORAL TABLET SEQUENTIAL         | DELETION | 8/1/2025  |   |                  |
| APTOM 200 MG ORAL TABLET                     | ESLICARBAZEPINE ACETATE 200 MG ORAL TABLET           | DELETION | 8/1/2025  |   |                  |
| APTOM 400 MG ORAL TABLET                     | ESLICARBAZEPINE ACETATE 400 MG ORAL TABLET           | DELETION | 8/1/2025  |   |                  |
| APTOM 600 MG ORAL TABLET                     | ESLICARBAZEPINE ACETATE 600 MG ORAL TABLET           | DELETION | 8/1/2025  |   |                  |
| APTOM 800 MG ORAL TABLET                     | ESLICARBAZEPINE ACETATE 800 MG ORAL TABLET           | DELETION | 8/1/2025  |   |                  |